Aage Haugen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aage Haugen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Shanbeh Zienolddiny
National Institute of Occupational Health in Norway, 0033 Oslo, Norway
8 shared publications Vidar Skaug
Section of Toxicology, National Institute of Occupational Health, Oslo, Norway
8 shared publicationsDavid Ryberg
Department of Toxicology, National Institute of Occupational Health, Oslo, Norway
5 shared publications- David H. Phillips
Department of Analytical, Environmental and Forensic Sciences, School of Cancer and Pharmaceutical Sciences, King's College London, 150 Stamford Street, London SE1 9NH, UK
2 shared publications F. Stefania Falvella
Department of Experimental Oncology and Laboratories, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milan, Italy
2 shared publications- Federico Canzian
Genomic Epidemiology Group German Cancer Research Center (DKFZ) Heidelberg Germany
2 shared publications
Latest Publications
- Open Access
- 19 January 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 28
Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
Amplifications of the transcription factor, SRY (sex determining region Y)-box 2 (SOX2), are common in non-small cell lung cancer (NSCLC). SOX2 signaling is important in maintaining the stem cell-like phenotype of cancer cells and contributes to the pathogenesis of lung cancer. TP53 is known to inhibit gene amplifications and to repress many stem cell-associated genes following DNA damage. The aim of this study was to investigate if TP53 mutational status affected SOX2 copy number variation and gene expression in early-stage NSCLC patients; moreover, to assess if TP53 regulates SOX2 expression in human lung cancer cells. 258 early-stage lung cancer patients were included in the study. Exons 4–9 in the TP53 gene were sequenced for mutations in tumor tissues. SOX2 copy number as well as TP53 and SOX2 gene expression were analyzed in tumor and in adjacent non-tumorous tissues by qPCR. TP53 and SOX2 were silenced using gene-specific siRNAs in human lung adenocarcinoma A427 cells, and the expression of TP53, SOX2 and subset of selected miRNAs was analyzed by qPCR. The odds ratios (ORs) for associations between copy number variation and lung cancer were estimated by conditional logistic regression, and the correlation between gene status and clinicopathological characteristics was assessed by Chi-square or Fisher’s exact test. Gene expression data was analyzed using nonparametric Mann–Whitney test. TP53 mutations were associated with an increased risk of acquiring a SOX2 copy number alteration (OR = 2.08, 95 % CI: 1.14–3.79, p = 0.017), which was more frequently occurring in tumor tissues (34 %) than in adjacent non-tumorous tissues (3 %). Moreover, SOX2 and TP53 expression levels were strongly correlated in tumor tissues. In vitro studies showed that a reduction in TP53 was associated with decreased SOX2 expression in A427 cells. Furthermore, TP53 knockdown reduced the miRNA hsa-miR-145, which has previously been shown to regulate SOX2 expression. TP53 signaling may be important in the regulation of SOX2 copy number and expression in NSCLC tumors, and the miRNA hsa-miR-145-5p may be one potential driver. This prompts for further studies on the mechanisms behind the TP53-induced regulation of SOX2 expression and the possible importance of hsa-miR-145 in lung cancer.
- 19 January 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 28
Open AccessMutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
Amplifications of the transcription factor, SRY (sex determining region Y)-box 2 (SOX2), are common in non-small cell lung cancer (NSCLC). SOX2 signaling is important in maintaining the stem cell-like phenotype of cancer cells and contributes to the pathogenesis of lung cancer. TP53 is known to inhibit gene amplifications and to repress many stem cell-associated genes following DNA damage. The aim of this study was to investigate if TP53 mutational status affected SOX2 copy number variation and gene expression in early-stage NSCLC patients; moreover, to assess if TP53 regulates SOX2 expression in human lung cancer cells. 258 early-stage lung cancer patients were included in the study. Exons 4–9 in the TP53 gene were sequenced for mutations in tumor tissues. SOX2 copy number as well as TP53 and SOX2 gene expression were analyzed in tumor and in adjacent non-tumorous tissues by qPCR. TP53 and SOX2 were silenced using gene-specific siRNAs in human lung adenocarcinoma A427 cells, and the expression of TP53, SOX2 and subset of selected miRNAs was analyzed by qPCR. The odds ratios (ORs) for associations between copy number variation and lung cancer were estimated by conditional logistic regression, and the correlation between gene status and clinicopathological characteristics was assessed by Chi-square or Fisher’s exact test. Gene expression data was analyzed using nonparametric Mann–Whitney test. TP53 mutations were associated with an increased risk of acquiring a SOX2 copy number alteration (OR = 2.08, 95 % CI: 1.14–3.79, p = 0.017), which was more frequently occurring in tumor tissues (34 %) than in adjacent non-tumorous tissues (3 %). Moreover, SOX2 and TP53 expression levels were strongly correlated in tumor tissues. In vitro studies showed that a reduction in TP53 was associated with decreased SOX2 expression in A427 cells. Furthermore, TP53 knockdown reduced the miRNA hsa-miR-145, which has previously been shown to regulate SOX2 expression. TP53 signaling may be important in the regulation of SOX2 copy number and expression in NSCLC tumors, and the miRNA hsa-miR-145-5p may be one potential driver. This prompts for further studies on the mechanisms behind the TP53-induced regulation of SOX2 expression and the possible importance of hsa-miR-145 in lung cancer.
- Open Access
- 1 July 2015
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (7) , 1037-1048
An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
- 1 July 2015
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (7) , 1037-1048
Open AccessAn Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
- Open Access
- 3 July 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (4) , R53
Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts
Introduction: Some studies have suggested that night work may be associated with an increased risk of breast cancer in nurses. We aimed to explore the role of circadian gene polymorphisms in the susceptibility to night work-related breast cancer risk. Methods: We conducted a nested case-control study of Norwegian nurses comprising 563 breast cancer cases and 619 controls within a cohort of 49,402 Norwegian nurses ages 35 to 74 years. We studied 60 single-nucleotide polymorphisms (SNPs) in 17 genes involved in the regulation of the circadian rhythm in cases and controls. The data were analyzed in relation to the two exposure variables "maximum number of consecutive night shifts ever worked" and "maximum number of consecutive night shifts worked for at least 5 years." The odds of breast cancer associated with each SNP was calculated in the main effects analysis and in relation to night shift work. The statistically significant odds ratios were tested for noteworthiness using two Bayesian tests: false positive report probability (FPRP) and Bayesian false discovery probability (BFDP). Results: In the main effects analysis, CC carriers of rs4238989 and GG carriers of rs3760138 in the AANAT gene had increased risk of breast cancer, whereas TT carriers of BMAL1 rs2278749 and TT carriers of CLOCK rs3749474 had reduced risk. The associations were found to be noteworthy using both the FPRP and BFDP tests. With regard to the effect of polymorphisms and night work, several significant associations were observed. After applying FPRP and BFDP in women with at least four night shifts, an increased risk of breast cancer was associated with variant alleles of SNPs in the genes AANAT (rs3760138, rs4238989), BMAL1 (rs2290035, rs2278749, rs969485) and ROR-b (rs3750420). In women with three consecutive night shifts, a reduced risk of breast cancer was associated with carriage of variant alleles of SNPs in CLOCK (rs3749474), BMAL1 (rs2278749), BMAL2 (rs2306074), CSNK1E (rs5757037), NPAS2 (rs17024926), ROR-b (rs3903529, rs3750420), MTNR1A (rs131113549) and PER3 (rs1012477). Conclusions: Significant and noteworthy associations between several polymorphisms in circadian genes, night work and breast cancer risk were found among nurses who had worked at least three consecutive night shifts.
- 3 July 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (4) , R53
Open AccessAnalysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts
Introduction: Some studies have suggested that night work may be associated with an increased risk of breast cancer in nurses. We aimed to explore the role of circadian gene polymorphisms in the susceptibility to night work-related breast cancer risk. Methods: We conducted a nested case-control study of Norwegian nurses comprising 563 breast cancer cases and 619 controls within a cohort of 49,402 Norwegian nurses ages 35 to 74 years. We studied 60 single-nucleotide polymorphisms (SNPs) in 17 genes involved in the regulation of the circadian rhythm in cases and controls. The data were analyzed in relation to the two exposure variables "maximum number of consecutive night shifts ever worked" and "maximum number of consecutive night shifts worked for at least 5 years." The odds of breast cancer associated with each SNP was calculated in the main effects analysis and in relation to night shift work. The statistically significant odds ratios were tested for noteworthiness using two Bayesian tests: false positive report probability (FPRP) and Bayesian false discovery probability (BFDP). Results: In the main effects analysis, CC carriers of rs4238989 and GG carriers of rs3760138 in the AANAT gene had increased risk of breast cancer, whereas TT carriers of BMAL1 rs2278749 and TT carriers of CLOCK rs3749474 had reduced risk. The associations were found to be noteworthy using both the FPRP and BFDP tests. With regard to the effect of polymorphisms and night work, several significant associations were observed. After applying FPRP and BFDP in women with at least four night shifts, an increased risk of breast cancer was associated with variant alleles of SNPs in the genes AANAT (rs3760138, rs4238989), BMAL1 (rs2290035, rs2278749, rs969485) and ROR-b (rs3750420). In women with three consecutive night shifts, a reduced risk of breast cancer was associated with carriage of variant alleles of SNPs in CLOCK (rs3749474), BMAL1 (rs2278749), BMAL2 (rs2306074), CSNK1E (rs5757037), NPAS2 (rs17024926), ROR-b (rs3903529, rs3750420), MTNR1A (rs131113549) and PER3 (rs1012477). Conclusions: Significant and noteworthy associations between several polymorphisms in circadian genes, night work and breast cancer risk were found among nurses who had worked at least three consecutive night shifts.
- Open Access
- 24 September 2010
- Published by Springer Nature in BMC Proceedings
- Vol. 4 (S2) , 1
Gene variants and lung cancer risk
- 24 September 2010
- Published by Springer Nature in BMC Proceedings
- Vol. 4 (S2) , 1
Open AccessGene variants and lung cancer risk
- 30 April 2007
- Published by Elsevier in Lung Cancer
- Vol. 56 (1) , 1-7
Common polymorphisms in D12S1034 flanking genes RASSF8 and BHLHB3 are not associated with lung adenocarcinoma risk
- 30 April 2007
- Published by Elsevier in Lung Cancer
- Vol. 56 (1) , 1-7
Common polymorphisms in D12S1034 flanking genes RASSF8 and BHLHB3 are not associated with lung adenocarcinoma risk
- 31 March 2007
- Published by Elsevier in Lung Cancer
- Vol. 55 (3) , 271-277
Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients’ survival
- 31 March 2007
- Published by Elsevier in Lung Cancer
- Vol. 55 (3) , 271-277
Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients’ survival
- 8 May 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (3) , 718-721
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
Lung cancer is the leading cause of cancer mortality in the world. Although exposure to carcinogens is considered to be the main cause, genetic variation may contribute to lung cancer risk. Murine double minute 2, MDM2, is a key regulator of p53 activity and recently a polymorphism in the promoter region of the MDM2 gene was characterized. This single nucleotide polymorphism, SNP309, was shown to influence MDM2 transcription, MDM2 protein levels and p53 activity. The aim of this study was to investigate whether this functionally important SNP is associated with risk of nonsmall cell lung cancer. The study consisted of 341 nonsmall cell lung cancer cases and 412 healthy controls of Norwegian origin. Our results indicate that the G/G genotype of SNP309 is associated with lung cancer risk with an odds ratio of 1.62 (95% CI: 1.06–2.50). Interestingly, the strongest effect of the polymorphism was seen among women. Females homozygous for SNP309 G/G had associated odds ratio 4.06 (1.29–12.8). We also explored the MDM2 SNP309 in relation to TP53 gene mutations and age at nonsmall cell lung cancer diagnosis. Our results indicate that the G/G genotype of SNP309 is associated with higher age at diagnosis in individuals with TP53 mutations (p = 0.037).
- 8 May 2006
- Published by Wiley in International Journal of Cancer
- Vol. 119 (3) , 718-721
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
Lung cancer is the leading cause of cancer mortality in the world. Although exposure to carcinogens is considered to be the main cause, genetic variation may contribute to lung cancer risk. Murine double minute 2, MDM2, is a key regulator of p53 activity and recently a polymorphism in the promoter region of the MDM2 gene was characterized. This single nucleotide polymorphism, SNP309, was shown to influence MDM2 transcription, MDM2 protein levels and p53 activity. The aim of this study was to investigate whether this functionally important SNP is associated with risk of nonsmall cell lung cancer. The study consisted of 341 nonsmall cell lung cancer cases and 412 healthy controls of Norwegian origin. Our results indicate that the G/G genotype of SNP309 is associated with lung cancer risk with an odds ratio of 1.62 (95% CI: 1.06–2.50). Interestingly, the strongest effect of the polymorphism was seen among women. Females homozygous for SNP309 G/G had associated odds ratio 4.06 (1.29–12.8). We also explored the MDM2 SNP309 in relation to TP53 gene mutations and age at nonsmall cell lung cancer diagnosis. Our results indicate that the G/G genotype of SNP309 is associated with higher age at diagnosis in individuals with TP53 mutations (p = 0.037).
- Open Access
- 14 March 2006
- Published by Wiley in International Journal of Cancer
- Vol. 118 (11) , 2899-2902
Msh2 deficiency increases susceptibility to benzo[a]pyrene‐induced lymphomagenesis
DNA mismatch repair (MMR) is essential for repair of single‐base mismatches and insertion/deletion loops. MMR proteins also participate in cellular response to DNA damaging agents such as various alkylating agents. Mice deficient in the MMR gene Msh2 develop tumors earlier after exposure to alkylating agents when compared to unexposed mice. The interaction between the MMR system and polycyclic aromatic hydrocarbons such as benzo[a]pyrene (B[a]P) has not been investigated in vivo. Here, we show that treatment of Msh2‐deficient mice with B[a]P enhances susceptibility to lymphomagenesis. Carrying at least one intact copy of the Msh2 gene had a protective effect. B[a]P treatment only induced lymphomas in 3 of the 40 (7.5%) mice with at least one intact copy of the Msh2 gene as compared to 13 of the 17 (76.5%) Msh2‐deficient mice and occurs only after a much longer time period. The B[a]P‐DNA adduct levels measured in lung, liver, spleen and forestomach of B[a]P‐treated Msh2−/− mice were not significantly different from B[a]P‐treated Msh2+/+ mice. In summary, the results suggest that B[a]P accelerates lymphomagenesis in Msh2‐deficient mice. Furthermore, Msh2 deficiency does not have any significant effect on B[a]P‐DNA adduct levels.
- 14 March 2006
- Published by Wiley in International Journal of Cancer
- Vol. 118 (11) , 2899-2902
Open AccessMsh2 deficiency increases susceptibility to benzo[a]pyrene‐induced lymphomagenesis
DNA mismatch repair (MMR) is essential for repair of single‐base mismatches and insertion/deletion loops. MMR proteins also participate in cellular response to DNA damaging agents such as various alkylating agents. Mice deficient in the MMR gene Msh2 develop tumors earlier after exposure to alkylating agents when compared to unexposed mice. The interaction between the MMR system and polycyclic aromatic hydrocarbons such as benzo[a]pyrene (B[a]P) has not been investigated in vivo. Here, we show that treatment of Msh2‐deficient mice with B[a]P enhances susceptibility to lymphomagenesis. Carrying at least one intact copy of the Msh2 gene had a protective effect. B[a]P treatment only induced lymphomas in 3 of the 40 (7.5%) mice with at least one intact copy of the Msh2 gene as compared to 13 of the 17 (76.5%) Msh2‐deficient mice and occurs only after a much longer time period. The B[a]P‐DNA adduct levels measured in lung, liver, spleen and forestomach of B[a]P‐treated Msh2−/− mice were not significantly different from B[a]P‐treated Msh2+/+ mice. In summary, the results suggest that B[a]P accelerates lymphomagenesis in Msh2‐deficient mice. Furthermore, Msh2 deficiency does not have any significant effect on B[a]P‐DNA adduct levels.
- 1 December 2005
- Vol. 125 (23) , 3283-5
[Molecular biology in the diagnosis of lung cancer].
Lung cancer is the most prevalent and deadly cancer in the world. Despite extensive efforts made in the development of diagnostic methods, the overall five-year survival rate remains low. Research articles and reviews. Significant progress has been made in understanding the molecular and cellular mechanisms and pathogenesis in lung cancer. In addition to abnormalities in proto-oncogenes and tumour suppressor genes, aberrant promoter hypermethylation is now recognised as an important component in lung cancer progression. Sensitive assays have been developed to assess promoter methylation in biological fluids that may be used in screening programmes and diagnosis of lung cancer. The development of gene expression profiling techniques has led to new approaches to lung cancer classification and diagnosis.
- 1 December 2005
- Vol. 125 (23) , 3283-5
[Molecular biology in the diagnosis of lung cancer].
Lung cancer is the most prevalent and deadly cancer in the world. Despite extensive efforts made in the development of diagnostic methods, the overall five-year survival rate remains low. Research articles and reviews. Significant progress has been made in understanding the molecular and cellular mechanisms and pathogenesis in lung cancer. In addition to abnormalities in proto-oncogenes and tumour suppressor genes, aberrant promoter hypermethylation is now recognised as an important component in lung cancer progression. Sensitive assays have been developed to assess promoter methylation in biological fluids that may be used in screening programmes and diagnosis of lung cancer. The development of gene expression profiling techniques has led to new approaches to lung cancer classification and diagnosis.
- Open Access
- 29 September 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 560-567
Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
Lung cancer is a leading cause of cancer mortality with an inter-individual difference in susceptibility to the disease. The inheritance of low-efficiency genotypes involved in DNA repair and replication may contribute to the difference in susceptibility. We investigated 44 single nucleotide polymorphisms (SNPs) in 20 DNA repair genes including nucleotide excision repair (NER) genes XPA , ERCC1 , ERCC2/XPD , ERCC4/XPF and ERCC5/XPG; base excision repair (BER) genes APE1 / APEX , OGG1 , MPG , XRCC1 , PCNA , POLB , POLι , LIG3 and EXO1; double-strand break repair (DSB-R) genes XRCC2 , XRCC3 , XRCC9 , NBS1 and ATR; and direct damage reversal (DR) gene MGMT/AGT . The study included 343 non-small cell lung cancer (NSCLC) cases and 413 controls from Norwegian general population. Our results indicate that SNPs in the NER genes ERCC1 (Asn118Asn, 15310G>C, 8902G>T), XPA (-4G>A), ERCC2 / XPD (Lys751Gln) and ERCC5/XPD (His46His); the BER genes APE1 / APEX (Ile64Val), OGG1 (Ser326Cys), PCNA (1876A>G) and XRCC1 (Arg194Trp, Arg280His, Arg399Gln); and the DSB-R genes ATR (Thr211Met), NBS1 (Glu185Gln), XRCC2 (Arg188His) and XRCC9 (Thr297Ile) modulate NSCLC risk. The level of polycyclic aromatic hydrocarbon–DNA (PAH–DNA) adducts in normal lung tissue from 211 patients was analysed. The variant alleles of XRCC1 (Arg280His), XRCC1 (Arg399Gln), ERCC1 (G8092T), ERCC5 (His46His) and MGMT/AGT (Lys178Arg) were more frequent in patients with PAH–DNA adduct levels lower than the mean whereas the XRCC1 (Arg194Trp) variant was more frequent in cases with higher adduct levels than the mean.
- 29 September 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 560-567
Open AccessPolymorphisms of DNA repair genes and risk of non-small cell lung cancer
Lung cancer is a leading cause of cancer mortality with an inter-individual difference in susceptibility to the disease. The inheritance of low-efficiency genotypes involved in DNA repair and replication may contribute to the difference in susceptibility. We investigated 44 single nucleotide polymorphisms (SNPs) in 20 DNA repair genes including nucleotide excision repair (NER) genes XPA , ERCC1 , ERCC2/XPD , ERCC4/XPF and ERCC5/XPG; base excision repair (BER) genes APE1 / APEX , OGG1 , MPG , XRCC1 , PCNA , POLB , POLι , LIG3 and EXO1; double-strand break repair (DSB-R) genes XRCC2 , XRCC3 , XRCC9 , NBS1 and ATR; and direct damage reversal (DR) gene MGMT/AGT . The study included 343 non-small cell lung cancer (NSCLC) cases and 413 controls from Norwegian general population. Our results indicate that SNPs in the NER genes ERCC1 (Asn118Asn, 15310G>C, 8902G>T), XPA (-4G>A), ERCC2 / XPD (Lys751Gln) and ERCC5/XPD (His46His); the BER genes APE1 / APEX (Ile64Val), OGG1 (Ser326Cys), PCNA (1876A>G) and XRCC1 (Arg194Trp, Arg280His, Arg399Gln); and the DSB-R genes ATR (Thr211Met), NBS1 (Glu185Gln), XRCC2 (Arg188His) and XRCC9 (Thr297Ile) modulate NSCLC risk. The level of polycyclic aromatic hydrocarbon–DNA (PAH–DNA) adducts in normal lung tissue from 211 patients was analysed. The variant alleles of XRCC1 (Arg280His), XRCC1 (Arg399Gln), ERCC1 (G8092T), ERCC5 (His46His) and MGMT/AGT (Lys178Arg) were more frequent in patients with PAH–DNA adduct levels lower than the mean whereas the XRCC1 (Arg194Trp) variant was more frequent in cases with higher adduct levels than the mean.